Replies to post #444241 on Anavex Life Sciences Corp (AVXL)

[williamssc]

Press release still stands. Thanks for pointing that out.

The trial met both its co-primary and key secondary endpoints, showing statistically significant and clinically meaningful improvement in cognition and function as measured by ADAS-Cog, ADCS-ADL, and CDR-SB, respectively.